Interferon-alfa-2b és ribavirin kombinált kezelés krónikus C hepatitisben. 100 Beteg egy évig tartó kezelése során szerzett tapasztalatok. Multicentrikus Tanulmány Munkacsoport.

Translated title of the contribution: Experience with combined interferon alpha-2b and ribavirin in the therapy of chronic hepatitis C. Experience with one-year therapy of 100 patients. Multicenter study

J. Fehér, G. Lengyel, T. Bálint

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It has been established that the long term interferon therapy in patients with chronic hepatitis C is able to produce sustained remission only in about 20 per cent of the cases. According to the newest data the combined interferon and ribavirin therapy significantly increases the remission of patients in naive, non-responder or relapsed cases. Clinical remission was confirmed by enzyme activity of alaninamino transferase (ALT) and HCV-RNA-PCR tests. In order to get exact data of the remission rate and the symptom free period, a prospective multicenter study has been introduced in Hungary. Ten leading hepatologic units have been involved into the trial. Till now the combined therapy with interferon-alfa-2b (3 MU, three times a week) and ribavirin--(1000-1200 mg daily) for one year has been finished in 100 cases with chronic hepatitis C. The mean value of ALT activity decreased near to the normal level, in 58 patients it was in the normal range. Side effects with mild or moderate grades have been found in 31 cases. The interim report of this multicenter study confirm the efficacy of this combined therapy in chronic hepatitis C.

Original languageHungarian
Pages (from-to)1235-1238
Number of pages4
JournalOrvosi Hetilap
Volume140
Issue number22
Publication statusPublished - May 30 1999

Fingerprint

interferon alfa-2b
Ribavirin
Chronic Hepatitis C
Multicenter Studies
Transferases
Interferons
Hungary
Therapeutics
Reference Values
Prospective Studies
RNA
Polymerase Chain Reaction
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{bb49670632ca4837a28df57556108949,
title = "Interferon-alfa-2b {\'e}s ribavirin kombin{\'a}lt kezel{\'e}s kr{\'o}nikus C hepatitisben. 100 Beteg egy {\'e}vig tart{\'o} kezel{\'e}se sor{\'a}n szerzett tapasztalatok. Multicentrikus Tanulm{\'a}ny Munkacsoport.",
abstract = "It has been established that the long term interferon therapy in patients with chronic hepatitis C is able to produce sustained remission only in about 20 per cent of the cases. According to the newest data the combined interferon and ribavirin therapy significantly increases the remission of patients in naive, non-responder or relapsed cases. Clinical remission was confirmed by enzyme activity of alaninamino transferase (ALT) and HCV-RNA-PCR tests. In order to get exact data of the remission rate and the symptom free period, a prospective multicenter study has been introduced in Hungary. Ten leading hepatologic units have been involved into the trial. Till now the combined therapy with interferon-alfa-2b (3 MU, three times a week) and ribavirin--(1000-1200 mg daily) for one year has been finished in 100 cases with chronic hepatitis C. The mean value of ALT activity decreased near to the normal level, in 58 patients it was in the normal range. Side effects with mild or moderate grades have been found in 31 cases. The interim report of this multicenter study confirm the efficacy of this combined therapy in chronic hepatitis C.",
author = "J. Feh{\'e}r and G. Lengyel and T. B{\'a}lint",
year = "1999",
month = "5",
day = "30",
language = "Hungarian",
volume = "140",
pages = "1235--1238",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "22",

}

TY - JOUR

T1 - Interferon-alfa-2b és ribavirin kombinált kezelés krónikus C hepatitisben. 100 Beteg egy évig tartó kezelése során szerzett tapasztalatok. Multicentrikus Tanulmány Munkacsoport.

AU - Fehér, J.

AU - Lengyel, G.

AU - Bálint, T.

PY - 1999/5/30

Y1 - 1999/5/30

N2 - It has been established that the long term interferon therapy in patients with chronic hepatitis C is able to produce sustained remission only in about 20 per cent of the cases. According to the newest data the combined interferon and ribavirin therapy significantly increases the remission of patients in naive, non-responder or relapsed cases. Clinical remission was confirmed by enzyme activity of alaninamino transferase (ALT) and HCV-RNA-PCR tests. In order to get exact data of the remission rate and the symptom free period, a prospective multicenter study has been introduced in Hungary. Ten leading hepatologic units have been involved into the trial. Till now the combined therapy with interferon-alfa-2b (3 MU, three times a week) and ribavirin--(1000-1200 mg daily) for one year has been finished in 100 cases with chronic hepatitis C. The mean value of ALT activity decreased near to the normal level, in 58 patients it was in the normal range. Side effects with mild or moderate grades have been found in 31 cases. The interim report of this multicenter study confirm the efficacy of this combined therapy in chronic hepatitis C.

AB - It has been established that the long term interferon therapy in patients with chronic hepatitis C is able to produce sustained remission only in about 20 per cent of the cases. According to the newest data the combined interferon and ribavirin therapy significantly increases the remission of patients in naive, non-responder or relapsed cases. Clinical remission was confirmed by enzyme activity of alaninamino transferase (ALT) and HCV-RNA-PCR tests. In order to get exact data of the remission rate and the symptom free period, a prospective multicenter study has been introduced in Hungary. Ten leading hepatologic units have been involved into the trial. Till now the combined therapy with interferon-alfa-2b (3 MU, three times a week) and ribavirin--(1000-1200 mg daily) for one year has been finished in 100 cases with chronic hepatitis C. The mean value of ALT activity decreased near to the normal level, in 58 patients it was in the normal range. Side effects with mild or moderate grades have been found in 31 cases. The interim report of this multicenter study confirm the efficacy of this combined therapy in chronic hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=0033617621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033617621&partnerID=8YFLogxK

M3 - Article

C2 - 10377734

AN - SCOPUS:0033617621

VL - 140

SP - 1235

EP - 1238

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 22

ER -